Measuring vaccine efficacy for both susceptibility to infection and reduction in infectiousness for prophylactic HIV-1 vaccines

Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology

Volumn 13, Issue 5, 1996, Pages 440-447

  Longini Jr , Ira M ^a   Datta, Susmita ^a   Halloran, M Elizabeth ^a  

^a EMORY UNIVERSITY   (United States)

Author keywords

Clinical trial; HIV; Phase III; Statistics; Vaccines

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS VACCINE; PLACEBO;

ARTICLE; CLINICAL TRIAL; DATA ANALYSIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HYPOTHESIS; IMMUNE DEFICIENCY; INFECTION RISK; PRIORITY JOURNAL; SEXUAL BEHAVIOR; SEXUAL TRANSMISSION; SEXUALLY TRANSMITTED DISEASE; STATISTICAL ANALYSIS; VACCINATION; VIRUS INFECTION;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 8044225290     PISSN: 10779450     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042560-199612150-00007     Document Type: Article

References (31)

1. World Health Organization. Weekly Epidemiological Record, no. 50 Geneva: WHO, 15 Dec 1995:353-57.
2. Halloran ME, Cochi S, Lieu T, Wharton M, Fehrs LJ. Epidemiologic and morbidity effects of routine immunization of preschool children with live-virus varicella vaccine in the US. Am J Epidemiol 1994;140:81-104.
3. Fast PE, Sawyer LA, Wescott SL. Clinical considerations in vaccine trials with special reference to candidate HIV vaccines. In: Powell MF, Newman MJ, eds. Vaccine design: the subunit adjuvant approach. New York: Plenum Press, 1995:97-134.
4. Jacquez JA, Koopman JS, Simon CP, Longini IM. The role of primary infection in the epidemics of HIV infection in gay cohorts. J Acquir Immune Defic Syndr 1994;7:1169-84.
5. Dixon DO, Rida WN, Fast PE, Hoth DF. HIV vaccine trials: some design issues including sample size calculation. Acquir Immune Defic Syndr 1993;6:485-96.
6. Halloran ME, Struchiner CJ. Causal inference for infectious diseases. Epidemiology 1995;6:142-51.
7. Halloran ME, Struchiner CJ. Vaccine effects: changes in susceptibility, infectiousness, contacts, direct and indirect effects. In: Proceedings of the III Brazilian, II Ibero American, Latin American Congress on Epidemiology, 1995, April 24-28; 1996. (in print).
8. Longini IM, Koopman JS, Haber M, Cotsonis GA. Statistical inference on risk-specific household and community transmission parameters for infectious diseases. Am J Epidemiol 1988;128:845-59.
9. Longini IM, Halloran ME, Haber M, Chen RT. Methods for estimating vaccine efficacy from outbreaks of acute infectious agents. Stat Med 1993;12:249-63.
10. Koopman J, Little RJ. Assessing HIV vaccine effects. Am J Epidemiol 1995;142:1113-20.
11. Longini IM, Koopman JS. Household and community transmission parameters from final distributions of infections in households. Biometrics 1982;38:115-26.
12. Magder L, Brookmeyer R. Analysis of infectious disease data from partners studies with unknown source of infection. Biometrics 1993;49:1110-6.
13. Rida WN. Assessing the effect of HIV vaccination. Stat Med 1996 (in print).
14. Datta S, Halloran ME, Longini IM. Augmented HIV vaccine trial designs for estimating reduction in infectiousness and protective efficacy. Technical report 96-3, Department of Biostatistics, Emory University, 1996.
15. Agresti A. Categorical data analysis, New York: Wiley, 1990:426-9.
16. Cohen J. News and comment: Thailand weighs AIDS vaccine tests. Science 1995;270:904-7.
17. Altman LK. U.S.-Industry blueprint is drawn to smooth way for an AIDS vaccine. The New York Times 1996 Feb 13; Sect B:10 (col 1).
18. Khamboonruang C, Beyrer C, Natpratan C, Celetano DD, Nelson KE. Cohort development in northern Thailand: HIV incidence studies among male and female STD clinic users. In: Conference on Advances in AIDS Vaccine Development: 8th Annual National Cooperative Vaccine Development Groups for AIDS Meeting, Poster Abstracts, Program Book. Bethesda: National Institutes of Health, 1996:226.
19. Bollinger RC, Mehendale S, Gangakhedkar R, et al. HIV transmission in India: HIVNET update. In: Conference on Advances in AIDS Vaccine Development: 8th Annual National Cooperative Vaccine Development Groups for AIDS Meeting, Poster Abstracts, Program Book. Bethesda: National Institutes of Health, 1996:221.
20. Duerr A, Xai Z, Nagachinta T, Toanabutra S, Tansuhaj A, Nelson K. Probability of male-to-female HIV transmission among married couples in Chaing Mai, Thailand. In: X International Conference on AIDS, Yokohama, August 1994 (Abstract 105C).
21. Mastro TD, de Vincenzi I. Probabilities of sexual HIV-1 transmission. AIDS 1996;10(suppl A):S75-S82.
22. Sutter RW, Patriarca PA. Inactivated and live, attenuated poliovirus vaccines: mucosal immunity. In: Kurstak E, ed. Measles and poliomyelitis. New York: Springer-Verlag, 1993:279-94.
23. Putonen P, Thorstensson R, Albert J, et al. Infection of cynomolgus monkeys with HIV-2 protects against pathogenic consequences of a subsequent simian immunodeficiency virus infection. AIDS 1990;4:784-9.
24. Putonen P, Walther L, Zhang Y-J, et al. Long-term protection against SIV-induced disease in macaques vaccinated with attenuated HIV-2 vaccine. Nat Med 1995;1:914-8.
25. Halloran ME, Struchiner CJ, Spielman A. Modeling malaria vaccines II: Population effects of stage-specific malaria vaccines dependent on natural boosting. Math Biosci 1989;94:115-49.
26. Halloran ME, Longini IM, Struchiner CJ, Haber NJ, Brunet RC. Exposure efficacy and change in contact rates in evaluating HIV vaccines in the field. Stat Med 1994;13:357-77.
27. Blower SM, McLean AR. Prophylactic vaccines, risk behavior change, and the probability of eradicating HIV in San Francisco. Science 1994;265:1451-4.
28. Longini IM, Halloran ME. AIDS: modeling epidemic control [Letter to the Editor]. Science 1995;267:1250-1.
29. Longini IM, Clark WS, Haber M, Horsburgh R. The stages of HIV infection: Waiting times and infection transmission probabilities. In: Castillo-Chavez C, ed. Mathematical and statistical approaches to AIDS epidemiology, lecture notes in biomathematics, vol 83. New York: Springer-Verlag, 1989:112-37.
30. Jewell NP, Shiboski SC. Statistical analysis of HIV infectivity based on partner studies. Biometrics 1990;46:1133-50.
31. Koopman JS, Simon CP, Jacquez JA, Joseph J, Sattenspiel L, Park T. Sexual partner selectiveness effects on homosexual HIV transmission dynamics. J Acquir Immun Defic Syndr 1988;1:486-504.